Gilead Sciences (GILD) Releases Earnings Results, Beats Expectations By $0.07 EPS

Gilead Sciences (GILD) reported quarterly earnings results on Monday, Jul-25-2016. The company said it had a profit of $3.08 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $3.01. The company posted revenue of $7776.00 million in the period, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.15 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.

In a different news, on Jul 7, 2016, John F Milligan (President and CEO) sold 112,000 shares at $84.62 per share price. According to the SEC, on Jul 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $84.36 per share price. On Jul 6, 2016, Paul Rutherford Carter (EVP Commercial Ops) sold 2,000 shares at $83.12 per share price, according to the Form-4 filing with the securities and exchange commission.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Gilead Sciences

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.